On the other hand, atezolizumab blocks the interaction of PD-L1 expressed on tumor cells and tumor-infiltrating immune cells with both PD-1 and B7.1 which results in reduced immunosuppressive signals and enhanced T cell-mediated antitumor immunity [15,16]. Here, PDCD1 is linked to neoplasm.